



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov



B1a Data Sheet

CONFIRMATION NO. 2196

|                             |                                   |              |                        |                                     |
|-----------------------------|-----------------------------------|--------------|------------------------|-------------------------------------|
| SERIAL NUMBER<br>10/019,976 | FILING DATE<br>10/23/2001<br>RULE | CLASS<br>546 | GROUP ART UNIT<br>1625 | ATTORNEY<br>DOCKET NO.<br>PU3650USW |
|-----------------------------|-----------------------------------|--------------|------------------------|-------------------------------------|

## APPLICANTS

Eric Cleveland Bigham, Durham, NC;  
Michael Joseph Bishop, Durham, NC;  
David Harold Drewry, Durham, NC;  
Deanna Trojan Garrison, Durham, NC;  
Stephen Joseph Hodson, Durham, NC;  
Frank Navas III, Durham, NC;  
Jason D Speake, Durham, NC;

\*\* CONTINUING DATA *✓ 65*

THIS APPLICATION IS A 371 OF PCT/EP00/03848 04/28/2000

\*\* FOREIGN APPLICATIONS *✓ 65*

UNITED KINGDOM 9910110.7 04/30/1999

|  |   |                           |                   |                               |                            |
|--|---|---------------------------|-------------------|-------------------------------|----------------------------|
| Foreign Priority claimed <input checked="" type="checkbox"/> yes <input type="checkbox"/> no | 35 USC 119 (a-d) conditions <input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after<br>met | STATE OR<br>COUNTRY<br>NC | SHEETS<br>DRAWING | TOTAL<br>CLAIMS<br><i>252</i> | INDEPENDENT<br>CLAIMS<br>1 |
| Verified and<br>Acknowledged<br><i>Malvinae 65</i>   | Examiner's Signature<br><i>Malvinae 65</i>  | Initials                  |                   |                               |                            |

## ADDRESS

23347

## TITLE

Imidazoline derivatives as alpha-1a adrenoceptor ligands

|                               |   |  |
|-------------------------------|---|--|
| FILING FEE<br>RECEIVED<br>980 | FEES: Authority has been given in Paper<br>No. _____ to charge/credit DEPOSIT ACCOUNT<br>No. _____ for following: | <input type="checkbox"/> All Fees<br><input type="checkbox"/> 1.16 Fees ( Filing )<br><input type="checkbox"/> 1.17 Fees ( Processing Ext. of<br>time )<br><input type="checkbox"/> 1.18 Fees ( Issue )<br><input type="checkbox"/> Other<br><input type="checkbox"/> Credit |
|-------------------------------|---|--|